Arturo Loaiza-Bonilla, MD, MSEd, FACP

Artificial intelligence may act as a force multiplier, with the automation of menial tasks enabling more time for clinicians to engage with patients.

Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.

Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.

An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.